‌

US Patent 7019193 Treatments using transgenic goat produced antithrombin III

Patent 7019193 was granted and assigned to GTC BIOTHERAPEUTICS, INC. on March, 2006 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Current Assignee

GTC BIOTHERAPEUTICS, INC.

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Harry M. Meade0

Edward S. Cole0

Paul Ditullio0

Date of Patent

March 28, 2006

0

Patent Application Number

101886580

Date Filed

July 2, 2002

0

Patent Primary Examiner

0

Patent abstract

This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7019193 Treatments using transgenic goat produced antithrombin III

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.